Vital Neutraceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 07-01-2025
- Paid Up Capital ₹ 0.33 M
as on 07-01-2025
- Company Age 29 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.67 M
as on 07-01-2025
- Revenue -39.47%
(FY 2021)
- Profit -33.80%
(FY 2021)
- Ebitda -20.95%
(FY 2021)
- Net Worth 12.83%
(FY 2021)
- Total Assets 10.14%
(FY 2021)
About Vital Neutraceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.33 M.
The company currently has active open charges totaling ₹8.67 M.
Ganesh Kamath and Suparna Kamath serve as directors at the Company.
- CIN/LLPIN
U74999MH1995PTC087893
- Company No.
087893
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 May 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Vital Neutraceuticals Private Limited offer?
Vital Neutraceuticals Private Limited offers a wide range of products and services, including Flavours & Aromatics, Fruit Flavor.
Who are the key members and board of directors at Vital Neutraceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ganesh Kamath  | Director | 01-May-1995 | Current |
| Suparna Kamath | Director | 01-May-1995 | Current |
Financial Performance of Vital Neutraceuticals.
Vital Neutraceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 39.47% decrease. The company also saw a substantial fall in profitability, with a 33.8% decrease in profit. The company's net worth Soared by an impressive increase of 12.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vital Neutraceuticals?
In 2021, Vital Neutraceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Nov 2020 | ₹0.74 M | Open |
Others Creation Date: 18 May 2016 | ₹0.88 M | Open |
Dombivli Nagrik Sahakari Bank Ltd. Creation Date: 22 Feb 2002 | ₹1.65 M | Open |
How Many Employees Work at Vital Neutraceuticals?
Unlock and access historical data on people associated with Vital Neutraceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vital Neutraceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vital Neutraceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
